CHMP Backs First Anti-CGRP in Europe for Migraine
If approved, rimegepant would be the first CGRP receptor antagonist available in Europe and the only migraine medication approved for both acute and preventive treatment in adults.
International Approvals
source https://www.medscape.com/viewarticle/969451?src=rss
International Approvals
source https://www.medscape.com/viewarticle/969451?src=rss
Comments
Post a Comment